Diabetes Research Today is a free monthly online journal that collates and summarizes the latest research about Diabetes, including details on insulin, type i, type ii, diet, treatment, prevention.

Update: vildagliptin for the treatment of Type 2 diabetes.

Garber AJ, Sharma MD

Professor of Medicine, Biochemistry & Molecular Biology, and Molecular & Cellular Biology, Baylor College of Medicine, Division of Diabetes, Endocrinology & Metabolism, 1709 Dryden, Suite 1000, Houston, TX 77030, USA. agarber@bcm.edu

Vildagliptin is a selective inhibitor of dipeptidyl peptidase-4, and prevents the rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Vildagliptin has been evaluated in > 4800 patients in nine Phase III studies in the range of 24 - 52 weeks in duration: four placebo- or active-controlled monotherapy trials that enrolled drug-naive patients; four add-on studies in which vildagliptin was added to a stable regimen of either metformin, a sulfonylurea, a thiazolidinedione or insulin; and a study in which an initial combination of vildagliptin plus pioglitazone in drug-naive patients was evaluated. Across studies, vildagliptin was effective in reducing HbA(1c), had a low risk of hypoglycemia and was weight-neutral and well tolerated.

Published 21 December 2007 in Expert Opin Investig Drugs, 17(1): 105-13.
Full-text of this article is available online (may require subscription).

© 2004-2008 Diabetes Research Today. All Rights Reserved.